FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis

FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis Print this page Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically… Read More: FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with… »

Study shows PE-owned hospitals increased charges, profitability while some care metrics improved

Dive Brief: Private equity investment appears to have an impact on the way hospitals conduct business, resulting in significantly higher charges and huge surges in profitability, according to a new study in JAMA Internal Medicine. Researchers from Harvard Medical School, the Harvard T.H. Chan School of Public Health and Massachusetts General Hospital compared the operations of… Read More: Study shows PE-owned hospitals increased charges, profitability while some care… »